diabetes

SanuWave: A Novel Approach to Diabetic Foot Ulcers, and a $20BN Chronic Wound Market

April 8, 2013 OneMedPlace Team 0

Investors and company executives may be “shocked” to learn that the chronic wound market size is estimated at $20 billion, according to AdvaMed.
Alpharetta, Ga.-based SanuWave (SNWV) looks to reduce that sticker shock. The company is developing potentially game-changing extracorp real shock wave technology for chronic wound care, cardiovascular, neurological and orthopedic conditions: its portfolio of shock wave therapies that sends ‘shockwaves’ through damaged cells, an action that stimulates the healing process.

Glysure CEO Discusses Real-Time Glucose Monitoring Technology, ISO 13485 Certification and CE Mark

March 18, 2013 OneMedPlace Team 0

As part of our expert series on the state of the industry, OneMedRadio spoke with Glysure CEO Chris Jones to discuss this recent news and learn about this unique technology. Jones also discussed trends in the industry affecting company growth and investment strategy, including reimbursement issues, evolving exit strategy, and the move away from normative medicine.

RELEASE: Glysure Earns ISO 13485 Certification

March 6, 2013 OneMedPlace Team 0

GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced that it has achieved ISO 13485 certification, the global standard for the requirements of a quality management system for the design, manufacture and distribution of medical devices. By establishing a quality management system that meets international regulatory and customer requirements, GlySure has set the foundation for its European clinical trials.